Philip Morris International Announces Unconditional Offer for Vectura Group PLC

Philip Morris International Announces Closing of Fertin Pharma Acquisition; Advances PMI’s Goal of Becoming a Majority Smoke-Free Business by 2025 and Creates Growth Opportunities Beyond Nicotine

Philip Morris International (PMI) Increases Dividend by 4.2% to Annualized Rate of $5.00 per Share

Philip Morris International Inc. (PMI) Presents at the 2021 Barclays Global Consumer Staples Conference; Reaffirms 2021 Full-Year Reported Diluted EPS Forecast Range of $5.76 to $5.86

Philip Morris International Inc. to Host Webcast of Presentation at Barclays Global Consumer Staples Conference

Philip Morris International Publishes Business Transformation-Linked Financing Framework, Further Demonstrating Its Commitment to Accelerating the End of Smoking

Philip Morris International Launches New IQOS ILUMA in Japan to Accelerate the Achievement of a Smoke-Free Future

Philip Morris International Enters Tender Period with Vectura Shareholders Following Unanimous Recommendation by Vectura Board

Philip Morris International Acquires Inhaled Drug Specialist OtiTopic; Growing Pipeline of “Beyond Nicotine” Inhaled Therapeutic Products

Philip Morris International Inc. Reports 2021 Second-Quarter Reported Diluted EPS of $1.39—Including Charges for Saudi Arabia Customs Assessments and Exit Costs—and Adjusted Diluted EPS of $1.57, Reflecting Organic Growth of 17.8%